ArticleFrontiers in endocrinology2025
Analysis of risk factors and predictive value of a nomogram for peripheral arterial disease in patients with type 2 diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms of Mangiferin on Neuroinflammation for Treating Major Depressive Disorder Based on Network Pharmacology and Bioinformatics Analysis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peripheral arterial disease (PAD) is a common macrovascular complication of type 2 diabetes mellitus (T2DM) that contributes to lower-limb morbidity and increased cardiovascular mortality. Early risk stratification is essential to guide screening and preventive measures; however, no comprehensive tool currently integrates demographic, clinical and hematologic factors to predict PAD in T2DM. Methods: In this retrospective cohort study, 426 adults with T2DM treated between January 2020 and December 2024 were stratified by PAD status (PAD, n = 136; non-PAD, n = 290). Risk factors were identified by multivariable logistic regression. A nomogram was constructed using the rms package in R and internally validated via bootstrap resampling (n = 1 000). Discrimination was assessed by area under the receiver operating characteristic curve (AUC) and concordance index (C-index), and calibration by Hosmer-Lemeshow goodness-of-fit and calibration plots. Results: Eleven independent predictors were incorporated: age; smoking; alcohol use; diabetes duration; systolic blood pressure; high-density lipoprotein cholesterol (HDL-C); low-density lipoprotein cholesterol (LDL-C); antihypertensive use; white blood cell count; platelet distribution width (PDW); and large platelet ratio (LPR). The nomogram achieved an AUC of 0.826 (95% CI 0.768-0.895), sensitivity of 78.6% and specificity of 89.6%. Internal validation yielded a bias-corrected C-index of 0.795 (95% CI 0.756-0.893), and Hosmer-Lemeshow P = 0.913, indicating good calibration. Conclusions: The proposed nomogram demonstrates robust discrimination and calibration for individualized PAD risk prediction in T2DM, supporting its potential to optimize targeted screening and preventive strategies pending external validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.